Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women  by Vongpatanasin, Wanpen et al.
Cardiac Issues in Women and the Elderly
Differential Effects of Oral Versus
Transdermal Estrogen Replacement Therapy on
C-Reactive Protein in Postmenopausal Women
Wanpen Vongpatanasin, MD, FACC,* Meryem Tuncel, MD,* Zhongyun Wang, MD,*
Debbie Arbique, RN,* Borna Mehrad, MD,* Ishwarlal Jialal, MD, PHD†
Dallas, Texas; and Sacramento, California
OBJECTIVES We investigated whether the route of estrogen replacement therapy (ET) is the major
determinant of C-reactive protein (CRP) in postmenopausal women.
BACKGROUND Recent studies demonstrated that oral ET causes a sustained increase in CRP, implicating a
proinflammatory effect. Because CRP is synthesized in the liver, we hypothesized that
estrogen-induced CRP elevation is related to first-pass hepatic metabolism.
METHODS In 21 postmenopausal women, we conducted a randomized, crossover, placebo-controlled
study to compare the effects of transdermal versus oral ET on CRP and inflammatory
cytokines. We measured CRP, interleukin (IL)-1-beta, IL-6, and tumor necrosis factor-alpha
before and after eight weeks of transdermal estradiol (E2) (100 g/day), oral conjugated
estrogen (CEE) (0.625 mg/day), or placebo. Insulin-like growth factor-1 (IGF-1), a
hepatic-derived anabolic peptide, was also measured.
RESULTS Transdermal E2 had no effect on CRP or IGF-1 levels. In contrast, eight weeks of oral
conjugated estrogens caused a more than twofold increase in CRP and a significant reduction
in IGF-1 (p  0.01) in the same women. The magnitude of increase in CRP was inversely
correlated to the decrease in IGF-1 (r  0.49, p  0.008). Neither transdermal E2 nor oral
CEE had any effects on the plasma concentrations of cytokines that promote CRP synthesis.
CONCLUSIONS In postmenopausal women, oral but not transdermal ET increased CRP by a first-pass
hepatic effect. An increase in CRP levels is accompanied by a reduction in IGF-1, an
anti-inflammatory growth factor. Because CRP is a powerful predictor of an adverse
prognosis in otherwise healthy postmenopausal women, the route of administration may be
an important consideration in minimizing the adverse effects of ET on cardiovascular
outcomes. (J Am Coll Cardiol 2003;41:1358–63) © 2003 by the American College of
Cardiology Foundation
The role of inflammation in the pathogenesis of cardiovas-
cular disease has been well established. Among markers of
systemic inflammation, C-reactive protein (CRP) is the
strongest independent predictor of myocardial infarction
and cardiovascular mortality in apparently healthy women
(1). A recent randomized trial and cross-sectional study
indicated that oral estrogen replacement therapy (ET) and
combined hormone replacement therapy (HT) caused a
sustained increase in CRP in postmenopausal women (2,3),
which may explain the increased risk of cardiovascular
events (4,5). In contrast, animal studies failed to demon-
strate such proinflammatory effects of estrogen given by
subcutaneous implantation or injection (6,7). Because CRP
is produced mainly in the liver, we hypothesized that the
increase in CRP after oral estrogen is due to exposure of the
liver to a high concentration of estrogen following gastro-
intestinal absorption. However, a comparison of the effects
of oral ET versus transdermal ET, which avoided first-pass
hepatic metabolism, on CRP and inflammatory cytokines
has not been performed in postmenopausal women.
Accordingly, the major aim of this study was to test
whether transdermal ET obviates the increase in CRP
produced by oral ET. In 21 postmenopausal women, we
performed a head-to-head comparison of the effects of
transdermal versus oral ET on plasma levels of CRP and
proinflammatory cytokines, using a randomized, crossover
design. To further determine whether changes in CRP
during oral ET are related to first-pass hepatic metabolism,
the serum levels of another peptide produced by the liver,
insulin-like growth factor-1 (IGF-1), were also measured in
the same women.
METHODS
The study was approved by the Institutional Review Board
of the University of Texas Southwestern Medical Center at
Dallas. After informed, written consent was obtained, 21
postmenopausal women (11 normotensive and 10 hyperten-
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sive) participated in a randomized, double-blinded, cross-
over trial. The rational for using a crossover design is that
the effect of multiple treatments can be assessed in a small
group of subjects, with the same power as that of a larger
parallel study. Generally, the total number of subjects
needed for a parallel trial is four times larger than the total
number of subjects needed for a two-period crossover trial
(8). Thus, a two-group parallel trial that requires total of 80
subjects (40 per group) would only need 20 subjects in a
two-period crossover design. In this regard, our three-
period crossover study of 21 subjects has the same power as
a parallel trial of 42 subjects per each treatment group or a
total of 120 subjects.
The clinical characteristics of normotensive and hyper-
tensive women are shown in Table 1. As expected, more
hypertensive women used diuretics than did normotensive
women (p  0.04). There were no statistically significant
differences in the proportion of women using an
angiotensin-converting enzyme inhibitor, angiotensin-
receptor blocker, or calcium channel blocker between the
two groups (p  0.05). The duration of menopause tended
to be longer in hypertensive than in normotensive women,
but the difference did not reach statistical significant (p 
0.08). None of subjects used aspirin or vitamin E. All of the
women had no history of any cardiovascular disease, were at
least one year from their last menstrual period, had a serum
estradiol (E2) concentration 40 pg/ml before study enroll-
ment, and had received no hormonal therapy for at least
four weeks before the study. This duration was determined
to be adequate to allow inflammatory markers to return to
baseline in our pilot study.
All postmenopausal women received the following three
regimens in random order: 1) transdermal E2 (Climara;
Berlex Laboratories, Wayne, New Jersey) at 100 g/day
plus oral placebo for eight weeks; 2) oral conjugated equine
estrogen (CEE) (Premarin; Wyeth-Ayerst, Madison, New
Jersey) at 0.625 mg plus a placebo patch for eight weeks; and
3) a placebo patch plus oral placebo for eight weeks. For
blinding purpose, the placebo patch (Berlex Laboratories)
and oral placebo with an identical appearance to the active
patch and pills were used in the study. Each subject was
instructed to take the medication at the same time of the
day.
Laboratory assays. Serum and plasma samples were ob-
tained at baseline and after each treatment period, at the
same time of the day, and kept frozen at 70°C until
analysis. The estradiol-17-beta level was measured using
iodine-125-labeled radioimmunoassay kits (Mayo Clinic,
Rochester, Minnesota). The IGF-1 levels were measured by
radioimmunoassay after acid-ethanol extraction (Nichols
Institute Diagnostics, San Juan Capistrano, California).
Serum levels of CRP were measured with a highly sensitive
latex-enhanced immunonephelometric assay (Dade Behr-
ing, Deerfield, Illinois). Both inter-assay and intra-assay
coefficients of variation were 5%. Plasma interleukin
(IL)-1-beta, IL-6, and tumor necrosis factor-alpha (TNF-
alpha) were each processed as one batch and assayed in
triplicate, using highly sensitive ELISA kits (Human Quan-
tikine HS IL-1-beta, IL-6, and TNF immunoassays; R&D
Systems, Minneapolis, Minnesota). The intra-assay coeffi-
cient of variation was 5%.
Statistical analysis. Repeated measures analysis of variance
(ANOVA) was used to assess the differences between
Abbreviations and Acronyms
ET  estrogen replacement therapy
CEE  conjugated equine estrogen
HT  combined hormone replacement therapy
CRP  C-reactive protein
E2  estradiol
hs-CRP  highly sensitive C-reactive protein
IGF-1  insulin-like growth factor-1
IL  interleukin
TNF-alpha  tumor necrosis factor-alpha
Table 1. Baseline Characteristics of Postmenopausal Women Participating in the Study
Normotensive
Women (n  11)
Hypertensive
Women (n  10)
p
Value
Age (yrs) 53  1 60  3 0.10
Body weight (kg) 69.3  2.8 71.9  4.8 0.65
Body mass index (kg/m2) 26.0  1.2 27.7  1.5 0.37
Fasting plasma glucose (mg/dl) 78  6 84  5 0.46
Years after menopause 7.0  1.4 13.7  3.2 0.08
LDL cholesterol (mg/dl) 124  10 115  14 0.63
HDL cholesterol (mg/dl) 44  3 50  7 0.46
Total cholesterol to HDL cholesterol ratio 4.7  0.3 3.7  0.6 0.17
Triglycerides (mg/dl) 165  30 100  14 0.10
Concomitant medications
Statin 1 (9%) 2 (20%) 0.59
ACE inhibitor 0 2 (20%) 0.21
Angiotensin receptor blocker 0 1 (10%) 0.48
Diuretics 0 4 (40%) 0.04
Calcium channel blocker 0 3 (30%) 0.09
Data are presented as the mean value  SEM or number (%) of subjects.
ACE  angiotensin-converting enzyme; HDL  high-density lipoprotein; LDL  low-density lipoprotein.
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baseline, transdermal E2, placebo, and oral estrogen. Con-
trasts from these models were used for pair-wise compari-
sons. The CRP, IL-1-beta, IL-6, and TNF-alpha data were
analyzed after a natural logarithmic transformation.
Carryover effects were also tested using mixed linear models,
including treatment period, and carryover factors. Various
models were examined, and the carryover effect was highly
nonsignificant (p 0.80) in all models for log(e) CRP. The
0.05 level of significance was used for ANOVA, and the
0.01 level of significance was used for pair-wise tests to
adjust for multiple testing. Comparisons of continuous
variables between normotensive and hypertensive women
and between large and small responders were performed
with the unpaired t test at the 0.05 level of significance.
Comparisons of categorical variables between normotensive
and hypertensive women and between large and small
responders were performed with the Fisher exact test at the
0.05 level of significance. The Pearson correlation coeffi-
cient was used to assess the association between IGF-1 and
CRP levels. C-reactive protein, IL-1-beta, IL-6, and TNF-
alpha are expressed as the median value and interquartile
range. Estradiol and IGF-1 are expressed as the mean value
 SEM. Statistical analysis was performed with SAS
version 8.0 (SAS Institute Inc., Cary, North Carolina).
RESULTS
As expected, oral CEE cause more than twofold increase in
highly sensitive (hs)-CRP (p  0.01 vs. baseline and
placebo). However, in the same women, transdermal E2 had
no effect on hs-CRP, despite a similar increase in serum E2
levels (Table 2, Fig. 1). When the analysis was limited to the
effect of the first treatment each woman received, the CRP
levels were still increased significantly in subjects who
received oral CEE first (from 1.5 0.5 vs. 3.2 1.0 g/ml,
p  0.03), but not in those who received transdermal E2
first (from 2.45  0.87 to 2.88  0.89 g/ml, p  NS) or
placebo first (from 1.60  1.30 to 1.60  1.00 g/ml, p 
NS). This increase in hs-CRP after oral CEE was accom-
panied by a significant decrease in IGF-1 levels (from 130
11 to 103  9 ng/ml; p  0.01 vs. baseline) (Table 1).
Transdermal E2 had no effect on IGF-1. Changes in IGF-1
levels from baseline were inversely correlated to changes in
hs-CRP from baseline, regardless of the treatment each
woman received (r  0.49, p  0.008) (Fig. 2). Neither
transdermal E2 nor oral CEE had any effect on plasma
IL-1-beta, IL-6, or TNF-alpha concentrations (Table 2).
Compared with baseline, there were no significant
changes in the ratio of total cholesterol to high-density
lipoprotein cholesterol after eight weeks of transdermal E2,
placebo, or oral CEE (4.3  0.3 vs. 4.5  0.3, 4.6  0.3,
and 4.0  0.3, respectively). Women who developed large
increases in CRP after oral CEE (arbitrarily defined as an
increase in CRP above the median level of 224% from
baseline) did not significantly differ from those who devel-
oped small (224%) increases in CRP, in terms of age,
body mass index, plasma glucose, duration of menopause,
cigarette or alcohol use, previous hormone use, or concom-
itant use of other medications that may influence CRP
levels (Table 3).
A subset analysis of nine of 21 postmenopausal subjects
who had never received ET or HT at the time of enrollment
indicated that the average baseline CRP levels were similar
to those after eight weeks of placebo (1.6 0.5 vs. 1.7 0.6
g/ml, respectively), suggesting that the carryover effect, if
any, was minimal or nonexistent with this duration of
treatment.
DISCUSSION
Many previous studies have shown that estrogen increases
CRP (2,3,9), a proinflammatory marker that may contribute
to the increased risk of adverse cardiovascular events in
postmenopausal women receiving HT in large clinical trials
(4,5). In contrast, the major new finding from our study is
that an increase in CRP is not an obligatory property of
estrogen, but rather is directly related to first-pass hepatic
metabolism, and thus may be avoided by a transdermal route
of administration.
There is a paucity of direct experimental support for a
proinflammatory effect of estrogen in animals or humans. A
large body of published data indicates that, if anything,
estrogen exerts anti-inflammatory action. In female rats, a
subcutaneous injection of estrogen reduced serum CRP
levels (7). In male rabbit recipients of a cardiac allograft,
subcutaneous estrogen implantation reduced infiltration of
macrophage and T lymphocytes in the transplanted coro-
nary vessel and attenuated coronary allograft atherosclerosis
Table 2. Effects of Oral Versus Transdermal Estrogen Administration on C-Reactive Protein and Inflammatory Cytokines





Estradiol (pg/ml) 35  4 172  45†‡ 31  4 168  54†‡  0.01
IGF-1 (ng/ml) 130  11 103  9†‡§ 128  11 122  9  0.01
hs-CRP (g/ml) 1.50 (0.80–4.50) 3.70†‡§ (1.55–6.20) 1.15 (0.73–3.70) 1.40 (0.7–4.00)  0.001
IL-1-beta (pg/ml) 0.32 (0.23–0.43) 0.26 (0.19–0.33) 0.26 (0.18–0.71) 0.19 (0.08–0.39) NS
IL-6 (pg/ml) 1.48 (0.93–2.29) 1.19 (0.84–2.54) 1.42 (1.15–1.65) 1.27 (0.97–2.03) NS
TNF-alpha (pg/ml) 1.36 (0.65–2.31) 1.88 (0.66–2.64) 1.43 (0.81–2.39) 1.00 (0.74–2.36) NS
*For comparison between baseline and three treatment groups. †p  0.01 vs. baseline. ‡ p  0.01 vs. placebo. §p  0.01 vs. transdermal estrogen. Data are presented as the
mean value  SEM or median value (interquartile range).
ANOVA  analysis of variance; CEE  conjugated equine estrogen; hs-CRP  highly sensitive C-reactive protein; IGF-1  insulin-like growth factor-1; IL  interleukin;
NS  not significant; TNF  tumor necrosis factor.
1360 Vongpatanasin et al. JACC Vol. 41, No. 8, 2003
Estrogen and Inflammatory Markers April 16, 2003:1358–63
(6). In young transsexual men (10), transdermal E2 had no
effect on CRP, and it had either no effect (11) or decreased
CRP in postmenopausal women (12). However, in these
human studies, concomitant use of oral progestins, which
have been recently shown to attenuate the increase in CRP
during oral estrogen administration (13,14), may be respon-
sible for the failure of transdermal ET to increase CRP.
By using unopposed estrogen, we were able to provide
clear-cut evidence that the route of administration and
first-pass hepatic metabolism are the major determinants of
CRP. Our ability to show that oral CEE at 0.625 mg/day
(equivalent to transdermal E2 at 50 g/day) caused a robust
increase in CRP, whereas transdermal E2 at the twice larger
dose of 100 g/day had no effect on CRP in the same
women, further confirming the hypothesis. Because only
oral CEE was tested as oral ET in our study, we consider
the possibility that CRP may not increase with other oral
preparations. However, this is unlikely because oral
estradiol-17-beta and E2 valerate have also been shown to
increase CRP levels in postmenopausal women to a similar
extent (9,14). We also consider the possibility that oral
estrogen acts at the extrahepatic sites, such as monocytes, T
lymphocytes, and adipocytes, to stimulate release of proin-
flammatory cytokines, which promote hepatic synthesis of
CRP. Because a recent observational study (15) and our
randomized study demonstrate that levels of these inflam-
matory cytokines were unaffected by oral estrogen, we
believe that oral estrogen acts directly in the liver to increase
CRP.
Indeed, our hypothesis is supported by the concomitant
reduction in IGF-1, a polypeptide primarily produced by
the liver under the control of growth hormone. Previous
studies have indicated that oral ET decrease IGF-1 levels
through a first-pass hepatic effect, resulting in reduced
feedback inhibition and elevated levels of growth hormone
in postmenopausal women (16). These effects were not seen
with transdermal ET (16). The linear correlation between
the increase in CRP and the reduction in IGF-1 from
baseline in our study provides further support for a common
mechanism linked to first-pass hepatic metabolism, govern-
ing responses of these two proteins.
Mechanisms by which first-pass hepatic metabolism of
oral ET increases CRP are also unknown. It is unlikely to be
direct hepatic stimulation of CRP synthesis, because even
supraphysiologic levels of estrogen had no effect on hepatic
CRP messenger ribonucleic acid expression in female rats
Figure 1. Individual and summary data of all subjects showing C-reactive protein (CRP) levels before and after oral estrogen (left panel), placebo (middle
panel), and transdermal estrogen (right panel). Transdermal estrogen had no effect on CRP. Oral estrogen administration for eight weeks evoked a more
than twofold increase in CRP (*p  0.01 vs. baseline, placebo, and transdermal estrogen).
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(7). Alternatively, an estrogen-induced reduction in IGF-1,
a peptide recently shown to have an anti-inflammatory
property (17,18), may trigger a secondary increase in CRP
production. Levels of CRP have been shown to be elevated
in patients with hypopituitarism (19), and adult-onset
growth hormone deficiency and growth hormone replace-
ment in these patients restored IGF-1 and reduced CRP
levels (17). In contrasts, CRP levels are reduced in patients
with acromegaly, and the growth hormone receptor antag-
onist decreased IGF-1 and increased CRP (20). Further-
more, in children with severe burns, administration of
exogenous IGF-1 attenuated overproduction of CRP (18).
Regardless of the mechanism by which oral ET increases
CRP, this observation may have important clinical impli-
cations. C-reactive protein is not simply a strong indepen-
dent predictor of future cardiovascular events without a
specific pathogenetic role. It has also recently been shown to
decrease the expression of endothelial nitric oxide synthase
enzyme and production of the potent vasodilator nitric
oxide in human endothelial cell cultures (21,22). In addi-
tion, CRP has been shown to exert a direct proatherogenic
effect, promoting monocyte chemotaxis (23) and tissue
factor expression in monocytes, as well as endothelial
shedding of adhesion molecules in an ex vivo cellular model
(24). Whether CRP elevation during oral CEE directly
promotes atherosclerosis in postmenopausal women re-
mains to be established. Because a recent prospective,
observational study indicated that CRP is an independent
predictor of future cardiovascular events, even in healthy
women who used hormone replacement therapy (25), the
elevation in CRP induced by oral CEE is likely to have
clinical significance. Similarly, the lack of positive findings
and the presence of cardiovascular harm observed in several
recent multicenter trials of ET or HT on cardiovascular
outcomes or coronary artery dimensions may be partly due
to the use of an oral rather than transdermal route of
administration (4,26). Large prospective studies are needed
to determine the role of transdermal ET on coronary heart
disease or atherosclerosis prevention after menopause.
Figure 2. Scatter plots showing the inverse correlation between changes in
serum insulin-like growth factor-1 (IGF-1) from baseline and changes in
C-reactive protein (CRP) from baseline, regardless of the treatment each
woman received.
Table 3. Characteristics of Women With Large Versus Small Increases in C-Reactive Protein




(n  12) p Value
Age (yrs) 58  3 55  2 0.41
Body weight (kg) 67.1  2.7 73.2  4.1 0.23
Body mass index (kg/m2) 25.9  0.8 27.4  1.5 0.40
Fasting plasma glucose (mg/dl) 78  6 82  6.3 0.79
Years after menopause 7.8  1.5 13.3  3.5 0.17
LDL cholesterol (mg/dl) 122  9 117  14 0.78
HDL cholesterol (mg/dl) 47  4 48  5.2 0.99
Total cholesterol to HDL cholesterol ratio 4.7  0.3 4.5  0.5 0.35
Triglycerides (mg/dl) 153  31 120  28 0.43
Estradiol levels during oral CEE (pg/ml) 125  26 183  55 0.36
Cigarette use 0 4 (33%) 0.10
Alcohol use 3 (33%) 5 (42%) 1.00
Previous hormone use 4 (44%) 8 (67%) 0.40
History of hypertension 3 (33%) 5 (42%) 1.00
Concomitant medications
Statin 2 (22%) 1 (8%) 0.55
ACE inhibitor 1 (11%) 1 (8%) 1.00
Angiotensin receptor blocker 0 1 (8%) 1.00
Diuretics 2 (22%) 2 (17%) 1.00
Calcium channel blocker 1 (11%) 2 (17%) 1.00
Data are presented as the mean value  SEM or number (%) of subjects.
Abbreviations as in Tables 1 and 2.
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